Overview:
A new wave of drugs that achieve the targeted delivery of radioisotopes are rapidly gaining momentum and attracting significant excitement. As the discovery and development pipeline widens, and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver the cell-killing radioisotopes.
One area that is showing considerable promise is the incorporation of an isotope-chelating moiety into a peptide ligand for a cell surface receptor on the cancer cells of interest. In this webinar we will discuss strategies for the discovery and optimisation of new peptide ligands for such targets, as well as their synthesis, investigation of efficacy, metabolism and distribution, and ultimately their manufacture.
